An Honest overview of Viatris Inc. (VTRS) after Q4 2024 Results
Are Wall Street Analysts Favorable Towards Viatris Shares?
Stock Tumble after Q4 2024 Results
On February 27, 2025, Viatris Inc. (VTRS) disclosed its Q4 2024 revenues of $3.5 billion, undercutting analyst estimates. A failed FDA inspection at their Indore facility compounded the issue, leading to an estimated 2025 revenue reduction of $500 million and a $385 million impact on earnings from operations[1][2][4]. Thisincident caused a sizable 15% single-day stock price plunge[4].
Analyst and Ratings
The consensus among seven analysts remains a "Hold" rating, constituting one "Strong Buy," four "Holds," one "Moderate Sell," and one "Strong Sell." This configuration has remained identical in recent months[2][4].
For the upcoming year through December 2025, analysts expect VTRS' EPS to slide 15.5% year over year to $2.24[2]. The company has met or exceeded analysts' consensus estimates in two of the past four quarters, missing on the other two[2].
Price Targets and Upside Potential
The mean analyst price target clocks in at $11.32, with a Street-high goal of $14 implying an impressive 65% upside from present levels[2][5].
As of the date of publication, I, Kritika Sarmah, didn't hold any positions in any of the securities mentioned in this article. This content is purely informational. Learn more about our Disclosure Policy here.
Revisiting Viatris Inc. (VTRS) after Q4 2024 Results
Financial Performance and Future Guidance
Post Q4 2024, Viatris' revenues and earnings fell short of analyst projections. The company offered conservative guidance for 2025 revenues, forecasting figures between $13.5 billion and $14 billion[3][4].
Analyst Hesitation, Slight Optimism
The consensus rating among seven analysts is a "Hold," including one "Strong Buy," four "Holds," one "Moderate Sell," and one "Strong Sell," consistent in recent times[2][4].
EPS Forecast and Meeting Expectations
In the upcoming year ending in December 2025, analysts anticipate VTRS' EPS will wane 15.5% year over year, settling at $2.24[2]. The company has surpassed analysts' consensus estimates in two of the last four quarters but missed the mark on the other two[2].
Price Targets and Upward Mobility
The average analyst price target is $11.32 with a Street-high goal of $14, suggesting a substantial upside of 33.5-65.1% from current prices[2][4][5].
A Synopsis of Viatris Inc.'s (VTRS) Position Following Q4 2024 Results
| Metric | Value/Rating ||---------------------------|-------------------------------|| Q4 2024 Revenue | $3.5B (missed estimates) || Q4 2024 Adjusted EPS | $0.54 (missed estimates) || 2025 Revenue Guidance | $13.5B–$14B || 2025 EPS Forecast | $2.24 (-15.5% YoY) || Analyst Consensus | Hold (1 SB, 4 H, 1 MS, 1 SS) || Avg. Price Target | $11.32 || Price Target Range | $9.00–$14.10 || Implied Upside | ~33.5–65.1% || Recent Stock Drop | ~15% (Feb. 27, 2025) || EBITDA | $4.48B |
Despite the operational challenges after the FDA-related blunders, the analyst ratings are mixed, suggesting that Viatris might present potential value for long-term investors as it hovers near its 52-week low[2][4][5].
- The stock of Viatris Inc. (VTRS) experienced a significant 15% drop following underperformance in Q4 2024.
- After Q4 2024 results, VTRS' revenues and earnings fell short of analyst projections, yet the company expressed conservative guidance for 2025 revenues, forecasting figures between $13.5 billion and $14 billion.
- The consensus among seven analysts for Viatris Inc. remains a "Hold" rating, with the average price target at $11.32, suggesting an upside of approximately 33.5-65.1% from current prices.
- Despite the recent operational issues and stock dip, Viatris Inc.’s (VTRS) long-term potential for investors is suggested by the mixed analyst ratings, as the company hovers near its 52-week low.
